Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has granted inducement awards to 14 new employees. The awards consist of options to purchase up to 228,400 shares of common stock under the Company's 2023 Inducement Plan.
The stock options feature a four-year vesting schedule, with 25% vesting after one year and the remaining shares vesting monthly at a rate of 1/48th over the subsequent 36 months, contingent on continued employment with Syndax.
Syndax Pharmaceuticals (NASDAQ: SNDX), un'azienda biofarmaceutica in fase commerciale specializzata in terapie oncologiche, ha assegnato premi di incentivo a 14 nuovi dipendenti. I premi consistono in opzioni per acquistare fino a 228.400 azioni ordinarie nell'ambito del Piano di Incentivazione 2023 della Società.
Le opzioni azionarie prevedono un piano di maturazione quadriennale, con il 25% che matura dopo un anno e le azioni rimanenti che maturano mensilmente a un ritmo di 1/48 nei successivi 36 mesi, subordinatamente alla permanenza in servizio presso Syndax.
Syndax Pharmaceuticals (NASDAQ: SNDX), una empresa biofarmacéutica en etapa comercial enfocada en terapias contra el cáncer, ha otorgado premios de incentivo a 14 nuevos empleados. Los premios consisten en opciones para comprar hasta 228,400 acciones ordinarias bajo el Plan de Incentivos 2023 de la Compañía.
Las opciones sobre acciones tienen un calendario de adquisición de derechos de cuatro años, con el 25% que se adquiere después de un año y las acciones restantes que se adquieren mensualmente a razón de 1/48 durante los siguientes 36 meses, condicionado a la continuidad del empleo en Syndax.
Syndax Pharmaceuticals (NASDAQ: SNDX)는 암 치료에 중점을 둔 상업 단계의 바이오제약 회사로, 14명의 신입 직원에게 유인 보상을 부여했습니다. 이 보상은 회사의 2023년 유인 계획에 따라 최대 228,400주의 보통주를 매수할 수 있는 옵션으로 구성됩니다.
주식 옵션은 4년간의 베스팅 일정이 있으며, 1년 후 25%가 베스팅되고 나머지 주식은 이후 36개월 동안 매월 1/48씩 베스팅되며, Syndax에서 계속 근무하는 경우에 한합니다.
Syndax Pharmaceuticals (NASDAQ : SNDX), une société biopharmaceutique en phase commerciale spécialisée dans les thérapies contre le cancer, a accordé des primes d'incitation à 14 nouveaux employés. Ces primes consistent en des options d'achat pouvant aller jusqu'à 228 400 actions ordinaires dans le cadre du Plan d'Incitation 2023 de la Société.
Les options d'achat d'actions suivent un calendrier d'acquisition sur quatre ans, avec 25 % acquis après un an et les actions restantes acquises mensuellement à raison de 1/48 sur les 36 mois suivants, sous réserve de la poursuite de l'emploi chez Syndax.
Syndax Pharmaceuticals (NASDAQ: SNDX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase mit Fokus auf Krebstherapien, hat Anreizprämien an 14 neue Mitarbeiter vergeben. Die Prämien bestehen aus Optionen zum Kauf von bis zu 228.400 Aktien des Stammkapitals im Rahmen des Inducement-Plans 2023 des Unternehmens.
Die Aktienoptionen haben einen vierjährigen Vesting-Zeitplan, wobei 25 % nach einem Jahr vesten und die restlichen Aktien monatlich mit einer Rate von 1/48 über die folgenden 36 Monate vesten, vorausgesetzt, die Beschäftigung bei Syndax wird fortgesetzt.
- None.
- None.
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2025 the Company granted inducement awards to purchase up to 228,400 shares of common stock to 14 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
FAQ
What type of inducement awards did Syndax Pharmaceuticals (SNDX) grant in July 2025?
How many employees received Syndax (SNDX) inducement awards in July 2025?
What is the vesting schedule for Syndax's (SNDX) July 2025 inducement awards?
What is the purpose of Syndax Pharmaceuticals' (SNDX) inducement awards?
